786 related articles for article (PubMed ID: 30385782)
1. The small molecule alpha-synuclein misfolding inhibitor, NPT200-11, produces multiple benefits in an animal model of Parkinson's disease.
Price DL; Koike MA; Khan A; Wrasidlo W; Rockenstein E; Masliah E; Bonhaus D
Sci Rep; 2018 Nov; 8(1):16165. PubMed ID: 30385782
[TBL] [Abstract][Full Text] [Related]
2. Endogenous oligodendroglial alpha-synuclein and TPPP/p25α orchestrate alpha-synuclein pathology in experimental multiple system atrophy models.
Mavroeidi P; Arvanitaki F; Karakitsou AK; Vetsi M; Kloukina I; Zweckstetter M; Giller K; Becker S; Sorrentino ZA; Giasson BI; Jensen PH; Stefanis L; Xilouri M
Acta Neuropathol; 2019 Sep; 138(3):415-441. PubMed ID: 31011860
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of Prolyl Oligopeptidase Restores Spontaneous Motor Behavior in the α-Synuclein Virus Vector-Based Parkinson's Disease Mouse Model by Decreasing α-Synuclein Oligomeric Species in Mouse Brain.
Svarcbahs R; Julku UH; Myöhänen TT
J Neurosci; 2016 Dec; 36(49):12485-12497. PubMed ID: 27927963
[TBL] [Abstract][Full Text] [Related]
4. Prominent astrocytic alpha-synuclein pathology with unique post-translational modification signatures unveiled across Lewy body disorders.
Altay MF; Liu AKL; Holton JL; Parkkinen L; Lashuel HA
Acta Neuropathol Commun; 2022 Nov; 10(1):163. PubMed ID: 36371251
[TBL] [Abstract][Full Text] [Related]
5. The effects of the novel A53E alpha-synuclein mutation on its oligomerization and aggregation.
Lázaro DF; Dias MC; Carija A; Navarro S; Madaleno CS; Tenreiro S; Ventura S; Outeiro TF
Acta Neuropathol Commun; 2016 Dec; 4(1):128. PubMed ID: 27938414
[TBL] [Abstract][Full Text] [Related]
6. Transgenic Mice Expressing Human α-Synuclein in Noradrenergic Neurons Develop Locus Ceruleus Pathology and Nonmotor Features of Parkinson's Disease.
Butkovich LM; Houser MC; Chalermpalanupap T; Porter-Stransky KA; Iannitelli AF; Boles JS; Lloyd GM; Coomes AS; Eidson LN; De Sousa Rodrigues ME; Oliver DL; Kelly SD; Chang J; Bengoa-Vergniory N; Wade-Martins R; Giasson BI; Joers V; Weinshenker D; Tansey MG
J Neurosci; 2020 Sep; 40(39):7559-7576. PubMed ID: 32868457
[TBL] [Abstract][Full Text] [Related]
7. Endosulfine-alpha inhibits membrane-induced α-synuclein aggregation and protects against α-synuclein neurotoxicity.
Ysselstein D; Dehay B; Costantino IM; McCabe GP; Frosch MP; George JM; Bezard E; Rochet JC
Acta Neuropathol Commun; 2017 Jan; 5(1):3. PubMed ID: 28069058
[TBL] [Abstract][Full Text] [Related]
8. FTY720-Mitoxy reduces synucleinopathy and neuroinflammation, restores behavior and mitochondria function, and increases GDNF expression in Multiple System Atrophy mouse models.
Vidal-Martinez G; Segura-Ulate I; Yang B; Diaz-Pacheco V; Barragan JA; De-Leon Esquivel J; Chaparro SA; Vargas-Medrano J; Perez RG
Exp Neurol; 2020 Mar; 325():113120. PubMed ID: 31751571
[TBL] [Abstract][Full Text] [Related]
9. Overexpression of alpha synuclein disrupts APP and Endolysosomal axonal trafficking in a mouse model of synucleinopathy.
Lin S; Leitão ADG; Fang S; Gu Y; Barber S; Gilliard-Telefoni R; Castro A; Sung K; Shen R; Florio JB; Mante ML; Ding J; Spencer B; Masliah E; Rissman RA; Wu C
Neurobiol Dis; 2023 Mar; 178():106010. PubMed ID: 36702318
[TBL] [Abstract][Full Text] [Related]
10. Glucocerebrosidase Activity Modulates Neuronal Susceptibility to Pathological α-Synuclein Insult.
Henderson MX; Sedor S; McGeary I; Cornblath EJ; Peng C; Riddle DM; Li HL; Zhang B; Brown HJ; Olufemi MF; Bassett DS; Trojanowski JQ; Lee VMY
Neuron; 2020 Mar; 105(5):822-836.e7. PubMed ID: 31899072
[TBL] [Abstract][Full Text] [Related]
11. Alpha-synuclein pathology, microgliosis, and parvalbumin neuron loss in the amygdala associated with enhanced fear in the Thy1-aSyn model of Parkinson's disease.
Torres ERS; Stanojlovic M; Zelikowsky M; Bonsberger J; Hean S; Mulligan C; Baldauf L; Fleming S; Masliah E; Chesselet MF; Fanselow MS; Richter F
Neurobiol Dis; 2021 Oct; 158():105478. PubMed ID: 34390837
[TBL] [Abstract][Full Text] [Related]
12. ɑ-Synuclein strains and seeding in Parkinson's disease, incidental Lewy body disease, dementia with Lewy bodies and multiple system atrophy: similarities and differences.
Peelaerts W; Bousset L; Baekelandt V; Melki R
Cell Tissue Res; 2018 Jul; 373(1):195-212. PubMed ID: 29704213
[TBL] [Abstract][Full Text] [Related]
13. Lovastatin ameliorates alpha-synuclein accumulation and oxidation in transgenic mouse models of alpha-synucleinopathies.
Koob AO; Ubhi K; Paulsson JF; Kelly J; Rockenstein E; Mante M; Adame A; Masliah E
Exp Neurol; 2010 Feb; 221(2):267-74. PubMed ID: 19944097
[TBL] [Abstract][Full Text] [Related]
14. ⍺-Synuclein Structural Diversity and the Cellular Environment in ⍺-Synuclein Transmission Models and Humans.
Peelaerts W; Baekelandt V
Neurotherapeutics; 2023 Jan; 20(1):67-82. PubMed ID: 37052776
[TBL] [Abstract][Full Text] [Related]
15. Longitudinal live imaging of retinal α-synuclein::GFP deposits in a transgenic mouse model of Parkinson's Disease/Dementia with Lewy Bodies.
Price DL; Rockenstein E; Mante M; Adame A; Overk C; Spencer B; Duong-Polk KX; Bonhaus D; Lindsey J; Masliah E
Sci Rep; 2016 Jul; 6():29523. PubMed ID: 27389831
[TBL] [Abstract][Full Text] [Related]
16. Prion-like propagation of human brain-derived alpha-synuclein in transgenic mice expressing human wild-type alpha-synuclein.
Bernis ME; Babila JT; Breid S; Wüsten KA; Wüllner U; Tamgüney G
Acta Neuropathol Commun; 2015 Nov; 3():75. PubMed ID: 26612754
[TBL] [Abstract][Full Text] [Related]
17. Caspase-1 causes truncation and aggregation of the Parkinson's disease-associated protein α-synuclein.
Wang W; Nguyen LT; Burlak C; Chegini F; Guo F; Chataway T; Ju S; Fisher OS; Miller DW; Datta D; Wu F; Wu CX; Landeru A; Wells JA; Cookson MR; Boxer MB; Thomas CJ; Gai WP; Ringe D; Petsko GA; Hoang QQ
Proc Natl Acad Sci U S A; 2016 Aug; 113(34):9587-92. PubMed ID: 27482083
[TBL] [Abstract][Full Text] [Related]
18. The structural differences between patient-derived α-synuclein strains dictate characteristics of Parkinson's disease, multiple system atrophy and dementia with Lewy bodies.
Van der Perren A; Gelders G; Fenyi A; Bousset L; Brito F; Peelaerts W; Van den Haute C; Gentleman S; Melki R; Baekelandt V
Acta Neuropathol; 2020 Jun; 139(6):977-1000. PubMed ID: 32356200
[TBL] [Abstract][Full Text] [Related]
19. Systematic comparison of the effects of alpha-synuclein mutations on its oligomerization and aggregation.
Lázaro DF; Rodrigues EF; Langohr R; Shahpasandzadeh H; Ribeiro T; Guerreiro P; Gerhardt E; Kröhnert K; Klucken J; Pereira MD; Popova B; Kruse N; Mollenhauer B; Rizzoli SO; Braus GH; Danzer KM; Outeiro TF
PLoS Genet; 2014 Nov; 10(11):e1004741. PubMed ID: 25393002
[TBL] [Abstract][Full Text] [Related]
20. The alpha-synucleinopathies: Parkinson's disease, dementia with Lewy bodies, and multiple system atrophy.
Spillantini MG; Goedert M
Ann N Y Acad Sci; 2000; 920():16-27. PubMed ID: 11193145
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
